Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 8/20 | 0.35 |
| ▸ | ACACB | O00763 | 7/20 | 0.35 |
| ▸ | DLK1 | P80370 | 2/20 | 0.35 |
| ▸ | DRG1 | Q9Y295 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618647 | 0.90 | KARS1 (0.40) | KARS1MAP3K12ACACBDLK1DRG1 | |
| SCHEMBL17618649 | 0.90 | SCD (0.37) | MAP3K12ACACBDLK1DRG1 | |
| SCHEMBL17618540 | 0.90 | VCP (0.40) | CNR2MAP3K12ACACBDLK1 | |
| SCHEMBL19669052 | 0.88 | KARS1 (0.41) | KARS1RXRA | |
| SCHEMBL17618666 | 0.88 | KARS1 (0.41) | KARS1RXRA | |
| SCHEMBL19361174 | 0.86 | KARS1 (0.38) | KARS1MAP3K12RXRA | |
| SCHEMBL19361177 | 0.86 | MAP3K12 (0.37) | MAP3K12ACACB | |
| SCHEMBL19670226 | 0.85 | CNR2 (0.38) | CNR2KARS1MAP3K12DLK1DRG1 | |
| SCHEMBL19669049 | 0.85 | ACACB (0.34) | KARS1MAP3K12ACACB | |
| SCHEMBL17618509 | 0.83 | WNT3A (0.41) | KARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765075-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CNR2 2514/4885KARS1 1760/4885MAP3K12 2105/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | CNR2 2514/4885KARS1 1760/4885MAP3K12 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.